Valeo Pharma Inc. reported earnings results for the second quarter and six months ended April 30, 2023. For the second quarter, the company reported sales was CAD 13.56 million compared to CAD 4.77 million a year ago. Net loss was CAD 6.48 million compared to CAD 5.1 million a year ago. Basic loss per share from continuing operations was CAD 0.08 compared to CAD 0.06 a year ago.
For the six months, sales was CAD 26.72 million compared to CAD 9.01 million a year ago. Net loss was CAD 12.73 million compared to CAD 11.05 million a year ago. Basic loss per share from continuing operations was CAD 0.15 compared to CAD 0.14 a year ago.